COMPETITIVE COMPARISON
ONLY NOBIVAC® LYME OFFERS POWERFUL COMPARATIVE BENEFITS AND PROVEN SAFETY.
Newsroom
PREVENTS JOINT ABNORMALITIES
NOBIVAC® LYME IS SHOWN TO BE EFFECTIVE AGAINST SUBCLINICAL ARTHRITIS, IN ADDITION TO CLINICAL DISEASE5 Following vaccination with Nobivac® Lyme: No Borrelia burgdorferi were found in the joint No joint inflammation, stiffness, or lameness were observed5 40% of control dogs developed chronic joint inflammation5 27% of control dogs developed joint stiffness or lameness5 Dogs exhibited no signs […]
2. MORTALITY: THE ONLY LEPTOSPIROSIS VACCINE SHOWN TO BE EFFECTIVE AGAINST DISEASE AND MORTALITY
PROTECTION FOR DOGS FACING THE MOST SEVERE CHALLENGES21 No dogs vaccinated with Nobivac® Canine 1-DAPPv+L₄ died or required euthanasia 54% mortality and euthanasia in control groups, reflecting the severity of challenge Clinical efficacy results showed that Nobivac® Canine 1-DAPPv+L₄ also prevented1 Leptospiremia More than 85% of vaccinates had no leptospiremia; leptospires were cleared quickly from the blood […]
TICK CHALLENGE STUDY
NOBIVAC® LYME IS HIGHLY EFFECTIVE IN KILLING BORRELIA BURGDORFERI AND PREVENTING INFECTION5 Tick challenge study confirms effectiveness.5 Following vaccination with Nobivac® Lyme, no B. burgdorferi were found. The tick challenge study was a placebo-controlled trial involving thirty 8-week-old puppies. Dogs were challenged 3 weeks following second vaccination.
ANTIBODY ACTIVITY
THE BORRELIACIDAL DIFFERENCE Only Nobivac® Lyme induces borreliacidal activity against both OspA and OspC1,5,80 Not all antibody responses are the same. “Multi-Osp protection” that induces antibodies against Osps other than OspA and OspC has not been shown to be relevant5,29,30 Other Lyme vaccines may induce antibodies against OspC, but they are not borreliacidal—meaning they don’t kill Borrelia […]